<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>RIASTAP- fibrinogen injection, powder, lyophilized, for solution </strong><br>CSL Behring GmbH<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use RiaSTAP safely and effectively.  See full prescribing information for RiaSTAP.<br> <br>RiaSTAP, Fibrinogen Concentrate (Human)<br>For Intravenous Use, Lyophilized Powder for Reconstitution<br>Initial U.S. Approval: 2009</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>RECENT MAJOR CHANGES</span></h1>
<div><table width="60%">
<col align="left" valign="top" width="80%">
<col align="right" valign="top" width="20%">
<tbody class="Headless"><tr class="Botrule First Last Toprule">
<td align="left">Indications and Usage (<a href="#S1">1</a>)</td>
<td align="right">12/2011</td>
</tr></tbody>
</table></div>
</div>
<div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div>
<p class="Highlighta">RiaSTAP, Fibrinogen Concentrate (Human) is indicated for the treatment of acute <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> episodes in patients with congenital fibrinogen deficiency, including <span class="product-label-link" type="condition" conceptid="4083191" conceptname="Afibrinogenemia">afibrinogenemia</span> and <span class="product-label-link" type="condition" conceptid="4125644" conceptname="Hypofibrinogenemia">hypofibrinogenemia</span> (<a href="#S1">1</a>). </p>
<p class="Highlighta">The effectiveness of RiaSTAP is based on maximum clot firmness, which measures the structural integrity of a clot, reflecting the underlying effectiveness of the fibrinogen present to form a fibrin clot (<a href="#S14">14</a>). </p>
<p class="Highlighta">There are no controlled trials demonstrating a direct benefit on treatment of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> episodes with RiaSTAP. </p>
<p class="Highlighta">RiaSTAP is not indicated for dysfibrinogenemia. </p>
</div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div>
<p class="Highlighta"><span class="Bold">For intravenous use only. Reconstitute prior to use.</span> </p>
<p class="Highlighta"><span class="Bold">Should be administered under the supervision of a physician.</span> </p>
<ul>
<li>Dose (mg/kg body weight) =<br><span class="Underline">[Target level (mg/dL) - measured level (mg/dL)]</span><br>    1.7 (mg/dL per mg/kg body weight)</li>
<li>Dose when fibrinogen level is unknown: 70 mg/kg body weight (<a href="#S2.1">2.1</a>).</li>
<li>Monitoring of patient's fibrinogen level is recommended during treatment. A target fibrinogen level of 100 mg/dL should be maintained until hemostasis is obtained.</li>
<li>The injection rate should not exceed 5 mL per minute (<a href="#S2.3">2.3</a>).</li>
</ul>
</div>
<div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><ul>
<li>RiaSTAP is available as a single-use vial containing 900 mg to 1300 mg lyophilized fibrinogen concentrate powder for reconstitution (<a href="#S3">3</a>).</li>
<li>The actual fibrinogen potency for each lot is printed on the vial label and carton (<a href="#S3">3</a>).</li>
</ul></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><ul><li>Anaphylactic or severe reactions to RiaSTAP or its components (<a href="#S4">4</a>).</li></ul></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><ul>
<li>Monitor patients for early signs of allergic or <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span> and if necessary, discontinue administration and institute appropriate treatment (<a href="#S5.1">5.1</a>).</li>
<li>Thrombotic events have been reported in patients receiving RiaSTAP. Weigh the benefits of administration versus the risks of <span class="product-label-link" type="condition" conceptid="4130722" conceptname="Thrombosis">thrombosis</span> (<a href="#S5.2">5.2</a>)</li>
<li>RiaSTAP is made from pooled human plasma. Products made from human plasma may contain infectious agents, e.g., viruses and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent (<a href="#S5.3">5.3</a>).</li>
</ul></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<ul><li>The most serious adverse reactions observed are thrombotic episodes (<span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">pulmonary embolism</span>, <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>, <span class="product-label-link" type="condition" conceptid="4042396" conceptname="Deep thrombophlebitis">deep vein thrombosis</span>) and <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic reactions</span>. The most common adverse reactions observed in clinical studies (frequency &gt;1%) were <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> and <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> (<a href="#S6">6</a>).</li></ul>
<p class="Highlighta">  </p>
<p class="Highlighta"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact CSL Behring at 1-866-915-6958 or FDA at 1-800-FDA-1088 or <span class="Italics">www.fda.gov/medwatch.</span></span> </p>
</div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>USE IN SPECIFIC POPULATIONS</span></h1>
<div><ul>
<li>Pregnancy:  No human or animal data. Use only if clearly needed (<a href="#S8.1">8.1</a>).</li>
<li>Pediatric: Shorter half life and faster clearance than in adults has been observed. These results are difficult to interpret because of the limited number of subjects (n=4)(<a href="#S8.4">8.4</a>).</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div><div></div></div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION.</p>
<p class="HighlightsRevision">Revised: 4/2011</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">1	INDICATIONS AND USAGE</a></h1>
<h1><a href="#section-2" class="toc">2	DOSAGE AND ADMINISTRATION</a></h1>
<h2><a href="#section-2.1" class="toc">2.1	Treatment of Congenital Fibrinogen Deficiency</a></h2>
<h2><a href="#section-2.2" class="toc">2.2	Preparation and Reconstitution</a></h2>
<h2><a href="#section-2.3" class="toc">2.3	Administration</a></h2>
<h1><a href="#section-3" class="toc">3	DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4	CONTRAINDICATIONS</a></h1>
<h1><a href="#section-5" class="toc">5	WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">5.1	<span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Allergic Reactions</span></a></h2>
<h2><a href="#section-5.2" class="toc">5.2	<span class="product-label-link" type="condition" conceptid="4130722" conceptname="Thrombosis">Thrombosis</span></a></h2>
<h2><a href="#section-5.3" class="toc">5.3	Transmissible Infectious Agents</a></h2>
<h1><a href="#section-6" class="toc">6	ADVERSE REACTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">6.1	Clinical Studies Experience</a></h2>
<h2><a href="#section-6.2" class="toc">6.2	Postmarketing Experience</a></h2>
<h1><a href="#section-7" class="toc">8	USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-7.1" class="toc">8.1	Pregnancy</a></h2>
<h2><a href="#section-7.2" class="toc">8.2	Labor and Delivery</a></h2>
<h2><a href="#section-7.3" class="toc">8.3	Nursing Mothers</a></h2>
<h2><a href="#section-7.4" class="toc">8.4	Pediatric Use</a></h2>
<h2><a href="#section-7.5" class="toc">8.5	Geriatric Use</a></h2>
<h1><a href="#section-8" class="toc">11	DESCRIPTION</a></h1>
<h1><a href="#section-9" class="toc">12	CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-9.1" class="toc">12.1	Mechanism of Action</a></h2>
<h2><a href="#section-9.2" class="toc">12.2	Pharmacodynamic Action</a></h2>
<h2><a href="#section-9.3" class="toc">12.3	Pharmacokinetics</a></h2>
<h1><a href="#section-10" class="toc">14	CLINICAL STUDIES</a></h1>
<h1><a href="#section-11" class="toc">15	REFERENCES</a></h1>
<h1><a href="#section-12" class="toc">16	HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h1><a href="#section-13" class="toc">17	PATIENT COUNSELING INFORMATION</a></h1>
<h2><a href="#section-13.1" class="toc">17.1	<span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Allergic Reactions</span></a></h2>
<h2><a href="#section-13.2" class="toc">17.2	<span class="product-label-link" type="condition" conceptid="4130722" conceptname="Thrombosis">Thrombosis</span></a></h2>
<h2><a href="#section-13.3" class="toc">17.3	Transmissible Infectious Agents</a></h2>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="DLDE"></a><a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="S1"></a><a name="section-1"></a><p></p>
<h1>1	INDICATIONS AND USAGE</h1>
<p class="First">RiaSTAP<span class="Sup">®</span>, Fibrinogen Concentrate (Human) is indicated for the treatment of acute <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> episodes in patients with congenital fibrinogen deficiency, including <span class="product-label-link" type="condition" conceptid="4083191" conceptname="Afibrinogenemia">afibrinogenemia</span> and <span class="product-label-link" type="condition" conceptid="4125644" conceptname="Hypofibrinogenemia">hypofibrinogenemia</span>.</p>
<p style="border-left:1px solid;"><span class="XmChange">The effectiveness of RiaSTAP is based on maximum clot firmness, which measures the structural integrity of a clot, reflecting the underlying effectiveness of the fibrinogen present to form a fibrin clot (<span class="Italics">see <a href="#S14">Clinical Studies [14]</a></span>).</span></p>
<p style="border-left:1px solid;"><span class="XmChange">There are no controlled trials demonstrating a direct benefit on treatment of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> episodes with RiaSTAP.</span></p>
<p>RiaSTAP is not indicated for dysfibrinogenemia.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="S2"></a><a name="section-2"></a><p></p>
<h1>2	DOSAGE AND ADMINISTRATION</h1>
<p class="First"><span class="Bold">For intravenous use only. Reconstitute prior to use.</span></p>
<p><span class="Bold">Should be administered under the supervision of a physician</span><span class="Italics">.</span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="S2.1"></a><a name="section-2.1"></a><p></p>
<h2>2.1	Treatment of Congenital Fibrinogen Deficiency</h2>
<p class="First">RiaSTAP dosing, duration of dosing and frequency of administration should be individualized based on the extent of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, laboratory values, and the clinical condition of the patient. </p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2.1.1"></a><p></p>
<p class="First"><span class="Underline">RiaSTAP dose when baseline fibrinogen level is known</span></p>
<p>Dose should be individually calculated for each patient based on the target plasma fibrinogen level based on the type of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, actual measured plasma fibrinogen level and body weight<span class="Bold">, </span>using the following formula<span class="Italics"> (see <a href="#S12.3">Pharmacokinetics [12.3]</a>)</span>:</p>
<table width="100%">
<col align="center" valign="middle" width="100%">
<tbody class="Headless">
<tr class="First Toprule"><td align="center"><span class="Underline">[Target level (mg/dL) - measured level (mg/dL)]</span></td></tr>
<tr class="Botrule Last"><td align="center">1.7 (mg/dL per mg/kg body weight)</td></tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2.1.2"></a><p></p>
<p class="First"><span class="Underline">RiaSTAP dose when baseline fibrinogen level is not known</span></p>
<p>If the patient's fibrinogen level is not known, the recommended dose is 70 mg per kg of body weight administered intravenously.</p>
<p>Monitoring of patient's fibrinogen level is recommended during treatment with RiaSTAP. A target fibrinogen level of 100 mg/dL should be maintained until hemostasis is obtained.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S2.2"></a><a name="section-2.2"></a><p></p>
<h2>2.2	Preparation and Reconstitution</h2>
<p class="First">The procedures below are provided as general guidelines for preparation and reconstitution of RiaSTAP.</p>
<p>Do not use RiaSTAP beyond the expiration date. RiaSTAP contains no preservative. Use aseptic technique when preparing and reconstituting RiaSTAP.</p>
<p>Reconstitute RiaSTAP at room temperature as follows:</p>
<ol>
<li>Remove the cap from the product vial to expose the central portion of the rubber stopper.</li>
<li>Clean the surface of the rubber stopper with an antiseptic solution and allow it to dry.</li>
<li>Using an appropriate transfer device or syringe, transfer 50 mL of Sterile Water for Injection into the product vial.</li>
<li>Gently swirl the product vial to ensure the product is fully dissolved. <span class="Bold">Do not shake the vial.</span>
</li>
</ol>
<p>After reconstitution, the RiaSTAP solution should be colorless and clear to slightly opalescent. Inspect visually for particulate matter and discoloration prior to administration. Do not use if the solution is cloudy or contains particulates. Do not freeze RiaSTAP solution. Discard partially used vials.</p>
<p>RiaSTAP is stable for 8 hours after reconstitution when stored at 20-25ºC and should be administered within this time period.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S2.3"></a><a name="section-2.3"></a><p></p>
<h2>2.3	Administration</h2>
<p class="First">Do not mix RiaSTAP with other medicinal products or intravenous solutions, and should be administered through a separate injection site. </p>
<p>Use aseptic technique when administering RiaSTAP.</p>
<p>Administer RiaSTAP at room temperature by slow intravenous injection at a rate not exceeding 5 mL per minute.</p>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="S3"></a><a name="section-3"></a><p></p>
<h1>3	DOSAGE FORMS AND STRENGTHS</h1>
<p class="First">RiaSTAP is available as a single-use vial containing 900 mg to 1300 mg lyophilized fibrinogen concentrate powder for reconstitution with 50 mL of Sterile Water for Injection.</p>
<p>The actual fibrinogen potency for each lot is printed on the vial label and carton.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="S4"></a><a name="section-4"></a><p></p>
<h1>4	CONTRAINDICATIONS</h1>
<p class="First">RiaSTAP is contraindicated in individuals who have manifested severe <span class="product-label-link" type="condition" conceptid="4223759" conceptname="IgE-mediated allergic disorder">immediate hypersensitivity reactions</span>, including <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span> to RiaSTAP or its components.</p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="S5"></a><a name="section-5"></a><p></p>
<h1>5	WARNINGS AND PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.1"></a><a name="section-5.1"></a><p></p>
<h2>5.1	<span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Allergic Reactions</span></h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Allergic reactions</span> may occur. If symptoms of allergic or early signs of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span> (including <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">hives</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">generalized urticaria</span>, tightness of the chest, <span class="product-label-link" type="condition" conceptid="314754" conceptname="Wheezing">wheezing</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, and <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>) occur, immediately discontinue administration (<span class="Italics">see <a href="#S17.1">Patient Counseling Information [17.1]</a></span>). The treatment required depends on the nature and severity of the reaction.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.2"></a><a name="section-5.2"></a><p></p>
<h2>5.2	<span class="product-label-link" type="condition" conceptid="4130722" conceptname="Thrombosis">Thrombosis</span></h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="4130722" conceptname="Thrombosis">Thrombosis</span> may occur spontaneously in patients with congenital fibrinogen deficiency with or without the use of fibrinogen replacement therapy.<span class="Sup">1</span>  <span class="product-label-link" type="condition" conceptid="4185607" conceptname="Embolism">Thromboembolic events</span> have been reported in patients treated with RiaSTAP. Weigh the benefits of RiaSTAP administration versus the risk of <span class="product-label-link" type="condition" conceptid="4130722" conceptname="Thrombosis">thrombosis</span>. Patients receiving RiaSTAP should be monitored for signs and symptoms of <span class="product-label-link" type="condition" conceptid="4130722" conceptname="Thrombosis">thrombosis</span>. (<span class="Italics">see <a href="#S17.2">Patient Counseling Information [17.2]</a></span>)</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.3"></a><a name="section-5.3"></a><p></p>
<h2>5.3	Transmissible Infectious Agents</h2>
<p class="First">RiaSTAP is made from human plasma. Products made from human plasma may contain infectious agents (e.g., viruses and theoretically the Creutzfeldt-Jakob disease agent [CJD]) that can cause disease. The risk that such products will transmit an infectious agent has been reduced by screening plasma donors for prior exposure to certain viruses, by testing for the presence of certain current virus <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>, and by a process demonstrated to inactivate and/or remove certain viruses during manufacturing. <span class="Italics">(see <a href="#S11">Description [11]</a>)</span>. Despite these measures, such products may still potentially transmit disease. There is also the possibility that unknown infectious agents may be present in such products <span class="Italics">(see <a href="#S17.3">Patient Counseling Information [17.3]</a>)</span>. All <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> thought by a physician possibly to have been transmitted by this product should be reported by the physician or other healthcare provider to CSL Behring at 1-866-915-6958.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="S6"></a><a name="section-6"></a><p></p>
<h1>6	ADVERSE REACTIONS</h1>
<p class="First">The most serious adverse reactions that have been reported in clinical studies or through postmarketing surveillance following RiaSTAP treatment are allergic-<span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic reactions</span> and thromboembolic episodes, including <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>, <span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">pulmonary embolism</span>, <span class="product-label-link" type="condition" conceptid="4042396" conceptname="Deep thrombophlebitis">deep vein thrombosis</span>, and <span class="product-label-link" type="condition" conceptid="4278217" conceptname="Arterial thrombosis">arterial thrombosis</span>.</p>
<p>The most common adverse reactions that have been reported in clinical studies or through postmarketing surveillance following RiaSTAP treatment are <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span> and generalized reactions such as <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">chills</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="S6.1"></a><a name="section-6.1"></a><p></p>
<h2>6.1	Clinical Studies Experience</h2>
<p class="First"><span class="Italics">Because clinical studies are conducted under widely varying conditions, adverse reaction rates observed cannot be directly compared to rates in other clinical studies and may not reflect the rates observed in practice.</span></p>
<p>The most common adverse reactions observed in more than one subject in clinical studies (frequency &gt;1%) were <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> and <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S6.2"></a><a name="section-6.2"></a><p></p>
<h2>6.2	Postmarketing Experience</h2>
<p class="First"><span class="Italics">Because postmarketing reporting of adverse reactions is voluntary and from a population of uncertain size, it is not always possible to reliably estimate the frequency of these reactions or establish a causal relationship to product exposure.</span></p>
<p>Adverse reactions reported in patients receiving RiaSTAP for treatment of fibrinogen deficiency include allergic-<span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic reactions</span> (including <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, etc.), general reactions such as <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">chills</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> and thromboembolic complications such as <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>, <span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">pulmonary embolism</span>, and <span class="product-label-link" type="condition" conceptid="4042396" conceptname="Deep thrombophlebitis">deep vein thrombosis</span>.</p>
<p>The following adverse reactions, identified by system organ class, have shown a possible causal relationship with RiaSTAP.</p>
<ul>
<li>
<span class="Italics">Allergic-<span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic reactions</span>: </span><span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span><span class="Italics">,</span> <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span></li>
<li>
<span class="Italics">Cardiovascular:</span> <span class="product-label-link" type="condition" conceptid="4159647" conceptname="Thromboembolic disorder">thromboembolism</span>, <span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">pulmonary embolism</span> (<span class="Italics">see <a href="#S5.2">Warnings and Precautions, <span class="product-label-link" type="condition" conceptid="4130722" conceptname="Thrombosis">Thrombosis</span> [5.2]</a></span>)</li>
<li>
<span class="Italics">General/Body as a Whole:</span> <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">chills</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span></li>
</ul>
</div>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="S8"></a><a name="section-7"></a><p></p>
<h1>8	USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="S8.1"></a><a name="section-7.1"></a><p></p>
<h2>8.1	Pregnancy</h2>
<p class="First">Pregnancy Category C. Animal reproduction studies have not been conducted with RiaSTAP. It is not known whether RiaSTAP can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. RiaSTAP should be used during pregnancy only if clearly needed.</p>
</div>
<div class="Section" data-sectionCode="34079-4">
<a name="S8.2"></a><a name="section-7.2"></a><p></p>
<h2>8.2	Labor and Delivery</h2>
<p class="First">RiaSTAP has not been studied for use during labor and delivery.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="S8.3"></a><a name="section-7.3"></a><p></p>
<h2>8.3	Nursing Mothers</h2>
<p class="First">RiaSTAP has not been studied in nursing mothers with congenital fibrinogen deficiency.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="S8.4"></a><a name="section-7.4"></a><p></p>
<h2>8.4	Pediatric Use</h2>
<p class="First">RiaSTAP studies have included subjects below the age of 16 years. In the pharmacokinetic study <span class="Italics">(see <a href="#S12.3">Pharmacokinetics [12.3]</a>)</span>, 2 children (8 and 11 years), 3 adolescents (12, 14 and 16 years), were studied. Subjects less than 16 years of age (n = 4) had shorter half-life (69.9 ± 8.5h) and faster clearance (0.7 ± 0.1 mg/L) compared to adults (half-life: 82.3 ± 20.0h, clearance: 0.53 ± 0.1 mg/L). The number of subjects less than 16 years of age in this study limits statistical interpretation.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="S8.5"></a><a name="section-7.5"></a><p></p>
<h2>8.5	Geriatric Use</h2>
<p class="First">The safety and efficacy of RiaSTAP in the geriatric population has not been studied. There were an insufficient number of subjects in this age group to determine whether they respond differently from younger subjects.</p>
</div>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="S11"></a><a name="section-8"></a><p></p>
<h1>11	DESCRIPTION</h1>
<p class="First">RiaSTAP is a heat-treated, lyophilized fibrinogen (coagulation factor I) powder made from pooled human plasma.</p>
<p>Each vial contains 900 to 1300 mg fibrinogen, 400 to 700 mg human albumin, 375 to 660 mg L-arginine hydrochloride, 200 to 350 mg sodium chloride and 50 to 100 mg sodium citrate. Sodium hydroxide and hydrochloric acid may have been used to adjust the pH.</p>
<p>All plasma used in the manufacture of RiaSTAP is tested using FDA-licensed serological assays for <span class="product-label-link" type="condition" conceptid="4318957" conceptname="Hepatitis B surface antigen">hepatitis B surface antigen</span> and antibodies to HIV-1/2 and HCV. Additionally, the plasma is tested with FDA-licensed Nucleic Acid Testing (NAT) for HCV and HIV-1 and found to be non-reactive (negative). For HBV, an investigational NAT procedure is used; however, the significance of a negative result has not been established. In addition, the plasma has been tested by NAT for HAV and B19V. Only plasma that passed virus screening is used for production, and the limit for B19V in the fractionation pool is set not to exceed 10<span class="Sup">4</span> IU of B19V DNA per mL.</p>
<p>RiaSTAP is manufactured from cryoprecipitate into a glycine precipitate, which is then further purified by multiple precipitation/adsorption steps. The manufacturing process has been demonstrated to reduce the risk of virus transmission in an additive manner: cryoprecipitation, Al(OH)<span class="Sub">3</span> adsorption/glycine precipitation/Al(OH)<span class="Sub">3</span> adsorption, heat treatment (+60ºC for 20 hours in an aqueous solution), and two subsequent glycine precipitation steps (initial and main glycine precipitation steps). These steps have been validated independently in a series of <span class="Italics">in vitro</span> experiments for their capacity to inactivate and/or remove both enveloped and non-enveloped viruses. Table 1 shows the virus clearance during the manufacturing process for RiaSTAP, expressed as the mean log<span class="Sub">10</span> reduction factor (LRF).</p>
<a name="table1"></a><table width="100%">
<caption><span>Table 1:    Cumulative (Log<span class="Sub">10</span>) Virus Inactivation/Reduction in RiaSTAP</span></caption>
<col align="left" valign="middle" width="24%">
<col align="center" valign="middle" width="9%">
<col align="center" valign="middle" width="10%">
<col align="center" valign="middle" width="9%">
<col align="center" valign="middle" width="10%">
<col align="center" valign="middle" width="9%">
<col align="center" valign="middle" width="10%">
<col align="center" valign="middle" width="9%">
<col align="center" valign="middle" width="10%">
<thead>
<tr class="First">
<th class="Lrule Rrule" align="center" rowspan="3">Manufacturing Step</th>
<th class="Botrule Rrule" align="center" colspan="8">Virus Reduction Factor (log<span class="Sub">10</span>)</th>
</tr>
<tr class="Botrule">
<th class="Rrule" align="center" colspan="5">Enveloped viruses</th>
<th class="Rrule" align="center" colspan="3">Non-enveloped viruses</th>
</tr>
<tr class="Last">
<th class="Rrule" align="center">HIV</th>
<th class="Rrule" align="center">BVDV</th>
<th class="Rrule" align="center">WNV</th>
<th class="Rrule" align="center">HSV-1</th>
<th class="Rrule" align="center">PRV</th>
<th class="Rrule" align="center">HAV</th>
<th class="Rrule" align="center">CPV</th>
<th class="Rrule" align="center">B19V<a name="footnote-reference-1" href="#footnote-1" class="Sup">*</a>
</th>
</tr>
</thead>
<tfoot>
<tr class="First Last"><td align="left" colspan="9" valign="top">BVDV, bovine viral <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> virus, model for HCV<br>WNV, West Nile virus<br>HSV-1, herpes simplex virus type 1<br>CPV, canine parvovirus, model for B19V<br>n.d., not done</td></tr>
<tr><td colspan="9" align="left"><dl class="Footnote">
<dt><a name="footnote-1" href="#footnote-reference-1">*</a></dt>
<dd>B19V, human parvovirus B19, the virus elimination studies for parvovirus B19 employed a novel experimental infectivity assay utilizing clone of cell line UT7 that contains erythropoietic progeny cells. Virus titer was determined using an immunofluorescence-based detection method.</dd>
<dt><a name="footnote-2" href="#footnote-reference-2">†</a></dt>
<dd>PRV – as HSV-1 a herpes virus – is reduced by cryoprecipitation by 1.6 log<span class="Sub">10 </span>
</dd>
<dt><a name="footnote-3" href="#footnote-reference-3">‡</a></dt>
<dd>Not included in the calculation of the cumulative virus reduction factor.</dd>
</dl></td></tr>
</tfoot>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="left">Cryoprecipitation</td>
<td class="Rrule" align="center">n.d.</td>
<td class="Rrule" align="center">n.d.</td>
<td class="Rrule" align="center">n.d.</td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center">1.6<a name="footnote-reference-2" href="#footnote-2" class="Sup">†</a>
</td>
<td class="Rrule" align="center" rowspan="2">2.4 </td>
<td class="Rrule" align="center" rowspan="2">2.8</td>
<td class="Rrule" align="center">n.d.</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Al(OH)<span class="Sub">3</span> adsorption/ glycine precipitation/ Al(OH)<span class="Sub">3</span> adsorption</td>
<td class="Rrule" align="center">(2.8)<a name="footnote-reference-3" href="#footnote-3" class="Sup">‡</a>
</td>
<td class="Rrule" align="center">(1.5)<a href="#footnote-3" class="Sup">‡</a>
</td>
<td class="Rrule" align="center">n.d.</td>
<td class="Rrule" align="center">(0.9)<a href="#footnote-3" class="Sup">‡</a>
</td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center">n.d.</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Heat Treatment</td>
<td class="Rrule" align="center">≥ 5.7</td>
<td class="Rrule" align="center">≥ 9.1</td>
<td class="Rrule" align="center">≥ 8.3</td>
<td class="Rrule" align="center">≥ 8.1</td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center">≥ 4.3</td>
<td class="Rrule" align="center">1.6</td>
<td class="Rrule" align="center">≥ 4.5<a href="#footnote-1" class="Sup">*</a>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Glycine precipitation<br> (two subsequent steps)</td>
<td class="Rrule" align="center">3.9 </td>
<td class="Rrule" align="center">2.1 </td>
<td class="Rrule" align="center">n.d.</td>
<td class="Rrule" align="center">1.0 </td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center">(1.0)<a href="#footnote-3" class="Sup">‡</a>
</td>
<td class="Rrule" align="center">(1.6)<a href="#footnote-3" class="Sup">‡</a>
</td>
<td class="Rrule" align="center">n.d.</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left"><span class="Bold">Cumulative virus reduction (log<span class="Sub">10</span>)</span></td>
<td class="Rrule" align="center"><span class="Bold">≥ 9.6 </span></td>
<td class="Rrule" align="center"><span class="Bold">≥ 11.2 </span></td>
<td class="Rrule" align="center"><span class="Bold">≥ 8.3</span></td>
<td class="Rrule" align="center"><span class="Bold">≥ 9.1</span></td>
<td class="Rrule" align="center"><span class="Bold">1.6</span></td>
<td class="Rrule" align="center"><span class="Bold">≥ 6.7 </span></td>
<td class="Rrule" align="center"><span class="Bold">4.4</span></td>
<td class="Rrule" align="center"><span class="Bold">≥ 4.5</span></td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="S12"></a><a name="section-9"></a><p></p>
<h1>12	CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="S12.1"></a><a name="section-9.1"></a><p></p>
<h2>12.1	Mechanism of Action</h2>
<p class="First">Fibrinogen (factor I) is a soluble plasma glycoprotein with a molecular weight of about 340 kDa. The native molecule is a dimer and consists of three pairs of polypeptide chains (Aα, Bβ and γ). Fibrinogen is a physiological substrate of three enzymes: thrombin, factor XIIIa, and plasmin.</p>
<p>During the coagulation process, thrombin cleaves the Aα and Bβ chains releasing fibrinopeptides A and B (FPA and FPB, respectively).<span class="Sup">2</span>  FPA is separated rapidly and the remaining molecule is a soluble fibrin monomer (fibrin I). The slower removal of FPB results in formation of fibrin II that is capable of polymerization that occurs by aggregation of fibrin monomers.<span class="Sup">2</span>  The resulting fibrin is stabilized in the presence of calcium ions and by  activated factor XIII, which acts as a transglutaminase. Factor XIIIa-induced cross-linking of fibrin polymers renders the fibrin clot more elastic and more resistant to <span class="product-label-link" type="condition" conceptid="4299457" conceptname="Fibrinolysis">fibrinolysis</span>.<span class="Sup">3</span>  Cross-linked fibrin is the end result of the coagulation cascade, and provides tensile strength to a primary hemostatic platelet plug and structure to the vessel wall.</p>
</div>
<div class="Section" data-sectionCode="43681-6">
<a name="S12.2"></a><a name="section-9.2"></a><p></p>
<h2>12.2	Pharmacodynamic Action</h2>
<p class="First">Administration of RiaSTAP to patients with congenital fibrinogen deficiency replaces the missing, or low coagulation factor. Normal levels are in the range of 200 to 450 mg/dL.<span class="Sup">4</span></p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="S12.3"></a><a name="section-9.3"></a><p></p>
<h2>12.3	Pharmacokinetics</h2>
<p class="First">A prospective, open label, uncontrolled, multicenter pharmacokinetic study was conducted in 5 females and 9 males with congenital fibrinogen deficiency (<span class="product-label-link" type="condition" conceptid="4083191" conceptname="Afibrinogenemia">afibrinogenemia</span>), ranging in age from 8 to 61 years (2 children, 3 adolescents, 9 adults). Each subject received a single intravenous dose of 70 mg/kg RiaSTAP. Blood samples were drawn from the patients to determine the fibrinogen activity at baseline and up to 14 days after the infusion. The pharmacokinetic parameters of RiaSTAP are summarized in Table 2.</p>
<p>No statistically relevant difference was observed between males and females for fibrinogen activity. Subjects less than 16 years of age (n=4) had shorter half-life (69.9 ± 8.5) and faster clearance (0.73 ± 0.14) compared to subjects &gt;16 years of age. The number of subjects less than 16 years of age in this study limits statistical interpretations.</p>
<p>The incremental <span class="Italics">in vivo</span> recovery (IVR) was determined from levels obtained up to 4 hours post-infusion. The median incremental IVR was 1.7 mg/dL (range 1.30 – 2.73 mg/dL) increase per mg/kg. The median <span class="Italics">in vivo</span> recovery indicates that a dose of 70 mg/kg will increase patients' fibrinogen plasma concentration by approximately 120 mg/dL.</p>
<p>The pharmacokinetic analysis using fibrinogen antigen data (ELISA) was concordant with the fibrinogen activity (Clauss assay).</p>
<a name="table2"></a><table width="80%">
<caption><span>Table 2: Pharmacokinetic Parameters (n=14) for Fibrinogen Activity</span></caption>
<col align="left" valign="middle" width="60%">
<col align="center" valign="middle" width="40%">
<thead><tr class="First Last">
<th align="left">Parameters</th>
<th align="center">Mean ± SD (range)</th>
</tr></thead>
<tbody>
<tr class="First">
<td align="left">Half-life [hours]</td>
<td align="center">78.7 ± 18.13 (55.73-117.26)</td>
</tr>
<tr>
<td align="left">C<span class="Sub">max</span> [mg/dL]</td>
<td align="center">140 ± 27 (100-210)</td>
</tr>
<tr>
<td align="left">AUC for dose of 70 mg/kg [mg*hr/mL]</td>
<td align="center">124.3 ± 24.16 (81.73-156.40)</td>
</tr>
<tr>
<td align="left">Clearance [mL/h/kg]</td>
<td align="center">0.59 ± 0.13 (0.45-0.86)</td>
</tr>
<tr>
<td align="left">Mean residence time [hours]</td>
<td align="center">92.8 ± 20.11 (66.14-126.44)</td>
</tr>
<tr class="Last">
<td align="left">Volume of distribution at steady state [mL/kg]</td>
<td align="center">52.7 ± 7.48 (36.22-67.67)</td>
</tr>
</tbody>
</table>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="S14"></a><a name="section-10"></a><p></p>
<h1>14	CLINICAL STUDIES</h1>
<p class="First">The pharmacokinetic study evaluated the single-dose PK (<span class="Italics">see <a href="#S12.3">Pharmacokinetics [12.3]</a>)</span> and maximum clot firmness (MCF) in subjects with <span class="product-label-link" type="condition" conceptid="4083191" conceptname="Afibrinogenemia">afibrinogenemia</span>. MCF was determined by thromboelastometry (ROTEM) testing. MCF was measured to demonstrate functional activity of replacement fibrinogen when a fixed dose of RiaSTAP was administered. Clot firmness is a functional parameter that depends on: activation of coagulation, fibrinogen content of the sample and polymerization/crosslinking of the fibrin network. Thromboelastometry has been shown to be a functional marker for the assessment of fibrinogen content and for the effects of fibrinogen supplementation on clinical efficacy.<span class="Sup">5</span></p>
<p>For each subject, the MCF was determined before (baseline) and one hour after the single dose administration of RiaSTAP. RiaSTAP was found to be effective in increasing clot firmness in patients with congenital fibrinogen deficiency (<span class="product-label-link" type="condition" conceptid="4083191" conceptname="Afibrinogenemia">afibrinogenemia</span>) as measured by thromboelastometry. The study results demonstrated that the MCF values were significantly higher after administration of RiaSTAP than at baseline (<span class="Italics">see <a href="#table3">Table 3</a></span>). The mean change from pre-infusion to 1 hour post-infusion was 8.9 mm in the primary analysis (9.9 mm for subjects &lt; 16 years old and 8.5 mm for subjects ≥ 16 to &lt; 65 years old). The mean change in MCF values closely approximated the levels expected from adding known amounts of fibrinogen to plasma<span class="Italics"> in vitro.</span><span class="Sup">6</span> Hemostatic efficacy in acute <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> episodes, and its correlation with MCF, are being verified in a postmarketing study.</p>
<a name="table3"></a><table width="80%">
<caption><span>Table 3: MCF [mm] (ITT population)</span></caption>
<col align="left" valign="top" width="40%">
<col align="center" valign="top" width="10%">
<col align="center" valign="top" width="25%">
<col align="center" valign="top" width="25%">
<thead><tr class="First Last">
<th align="left">Time point</th>
<th align="center">n</th>
<th align="center">Mean ± SD</th>
<th align="center">Median (range)</th>
</tr></thead>
<tfoot>
<tr class="First Last"><td align="left" colspan="4" valign="top">MCF = maximum clot firmness; mm = millimeter; ITT = intention-to-treat.</td></tr>
<tr><td colspan="4" align="left"><dl class="Footnote">
<dt><a name="footnote-4" href="#footnote-reference-4">*</a></dt>
<dd>p-value was &lt;0.0001.</dd>
<dt><a name="footnote-5" href="#footnote-reference-5">†</a></dt>
<dd>The mean change was set to 0 for 2 subjects with missing MCF data.</dd>
</dl></td></tr>
</tfoot>
<tbody>
<tr class="First">
<td align="left">Pre-infusion</td>
<td align="center">13</td>
<td align="center">0 ± 0</td>
<td align="center">0 (0-0)</td>
</tr>
<tr>
<td align="left">1 hour post-infusion</td>
<td align="center">13</td>
<td align="center">10.3 ± 2.7</td>
<td align="center">10.0 (6.5-16.5)</td>
</tr>
<tr class="Last">
<td align="left">Mean change (primary analysis)<a name="footnote-reference-4" href="#footnote-4" class="Sup">*</a>
</td>
<td align="center">15<a name="footnote-reference-5" href="#footnote-5" class="Sup">†</a>
</td>
<td align="center">8.9 ± 4.4</td>
<td align="center">9.5 (0-16.5)</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="34093-5">
<a name="S15"></a><a name="section-11"></a><p></p>
<h1>15	REFERENCES</h1>
<ol>
<li>Peyvandi F, Haertal S, Knaub S, <span class="Italics">et al.</span> Incidence of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> symptoms in 100 patients with inherited <span class="product-label-link" type="condition" conceptid="4083191" conceptname="Afibrinogenemia">afibrinogenemia</span> or <span class="product-label-link" type="condition" conceptid="4125644" conceptname="Hypofibrinogenemia">hypofibrinogenemia</span>. <span class="Italics">J Thromb Haemost </span>2006; 4:1634-7.</li>
<li>Kreuz W, Meili E, Peter-Salonen K, <span class="Italics">et al.</span> Pharmacokinetic properties of a pasteurized fibrinogen concentrate. <span class="Italics">Transfusion and Apheresis Science</span> 2005;32:239-46.</li>
<li>Colman R, Clowes A, George J, <span class="Italics">et al. </span>Overview of Hemostasis. In: <span class="Italics">Hemostasis and <span class="product-label-link" type="condition" conceptid="4130722" conceptname="Thrombosis">Thrombosis</span>: Basic Principles and Clinical Practice</span> (5<span class="Sup">th</span> ed.). Colman R, Clowes A, George J, Goldhaber S, Marder VJ (eds.). Lippincott Williams &amp; Wilkins, Philadelphia 2006:11-14.</li>
<li>Kreuz W, Meili E, Peter-Salonen K, <span class="Italics">et al. </span>Efficacy and tolerability of a pasteurized human fibrinogen concentrate in patients with congenital fibrinogen deficiency. <span class="Italics">Transfusion and Apheresis Science</span> 2005;32:247-253.</li>
<li>Fries D, Innerhofer P, Reif C, <span class="Italics">et al.</span> The Effect of Fibrinogen Substitution on Reversal of Dilutional <span class="product-label-link" type="condition" conceptid="432585" conceptname="Blood coagulation disorder">Coagulopathy</span>: An <span class="Italics">In Vitro</span> Model. <span class="Italics">Anesth Analg</span> 2006; 102:347-351.</li>
<li>Kalina U, Stöhr HA, Bickhard H, <span class="Italics">et. al</span>. Rotational thromboelastography for monitoring of fibrinogen concentrate therapy in fibrinogen deficiency. <span class="Italics">Blood Coagulation and <span class="product-label-link" type="condition" conceptid="4299457" conceptname="Fibrinolysis">Fibrinolysis</span></span>. 2008; 19:777-783.</li>
</ol>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="S16"></a><a name="section-12"></a><p></p>
<h1>16	HOW SUPPLIED/STORAGE AND HANDLING</h1>
<p class="First">RiaSTAP is supplied in a single-use vial. Each carton contains one vial of RiaSTAP. The components used in the packaging for RiaSTAP are latex-free.</p>
<p>The actual potency of fibrinogen concentrate in milligram (mg) is stated on each RiaSTAP vial label and carton.</p>
<p>The following dosage form is available:</p>
<table width="80%">
<col align="left" valign="middle" width="30%">
<col align="left" valign="middle" width="70%">
<thead><tr class="First Last Toprule">
<th align="left">NDC Number</th>
<th align="left">RiaSTAP Vial</th>
</tr></thead>
<tbody><tr class="Botrule First Last Toprule">
<td align="left">63833-891-51</td>
<td align="left">Approximately 1 g (900 – 1300 mg)</td>
</tr></tbody>
</table>
<div class="Section" data-sectionCode="44425-7">
<a name="section-12.1"></a><p></p>
<p class="First">When stored at temperatures of 2-25°C (36-77°F), RiaSTAP is stable for the period indicated by the expiration date on the carton and vial label (up to 30 months). Keep RiaSTAP in its original carton until ready to use. Do not freeze. Protect from light.</p>
</div>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="S17"></a><a name="section-13"></a><p></p>
<h1>17	PATIENT COUNSELING INFORMATION</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="S17.1"></a><a name="section-13.1"></a><p></p>
<h2>17.1	<span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Allergic Reactions</span></h2>
<p class="First">Inform patients of the early signs of allergic or <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span> to RiaSTAP, including <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">hives</span>, <span class="product-label-link" type="condition" conceptid="4034235" conceptname="Tight chest">chest tightness</span>, <span class="product-label-link" type="condition" conceptid="314754" conceptname="Wheezing">wheezing</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, and <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span> (<span class="Italics">see <a href="#S5.1">Warnings and Precautions [5.1]</a></span>). Advise them to notify their physician immediately if they experience any of these symptoms.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S17.2"></a><a name="section-13.2"></a><p></p>
<h2>17.2	<span class="product-label-link" type="condition" conceptid="4130722" conceptname="Thrombosis">Thrombosis</span></h2>
<p class="First">Inform patients that <span class="product-label-link" type="condition" conceptid="4130722" conceptname="Thrombosis">thrombosis</span> with or without embolization may be due to the underlying fibrinogen deficiency and has been reported with the use of RiaSTAP. Any symptoms of thrombotic events such as unexplained pleuritic, chest and/or <span class="product-label-link" type="condition" conceptid="138525" conceptname="Pain in limb">leg pain</span> or <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, <span class="product-label-link" type="condition" conceptid="261687" conceptname="Hemoptysis">hemoptysis</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, <span class="product-label-link" type="condition" conceptid="317376" conceptname="Tachypnea">tachypnea</span> or unexplained <span class="product-label-link" type="condition" conceptid="4204047" conceptname="Neurological symptom">neurologic symptoms</span> should be reported to their physician immediately <span class="Italics">(see <a href="#S5.2">Warnings and Precautions [5.2]</a>)</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S17.3"></a><a name="section-13.3"></a><p></p>
<h2>17.3	Transmissible Infectious Agents</h2>
<p class="First">Inform patients that RiaSTAP is made from human plasma (part of the blood) and may contain infectious agents that can cause disease (e.g., viruses and, theoretically, the CJD agent). Explain the risk that RiaSTAP may transmit an infectious agent has been reduced by screening the plasma donors, by testing the donated plasma for certain virus <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>, and by a process demonstrated to inactivate and/or remove certain viruses during manufacturing (<span class="Italics">see <a href="#S5.3">Warnings and Precautions [5.3]</a></span>). Symptoms of a possible virus <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> include <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>, <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, or, in the case of <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span>, <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-14"></a><p></p>
<p class="First">Manufactured by:<br><span class="Bold">CSL Behring GmbH</span><br>35041 Marburg Germany<br>US License No. 1765</p>
<p>Distributed by:<br><span class="Bold">CSL Behring LLC</span><br>Kankakee, IL 60901 USA</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-15"></a><p></p>
<h1></h1>
<p class="First"><span class="Bold">PRINCIPAL DISPLAY PANEL - One Single-use Vial Carton</span></p>
<p><span class="Bold">NDC 63833-891-51</span></p>
<p>One Vial</p>
<p><span class="Bold">Fibrinogen Concentrate</span><br><span class="Bold">(Human)</span></p>
<p><span class="Bold Italics">RiaSTAP</span><span class="Bold"><span class="Sup">®</span></span></p>
<p>One single-use vial containing<br>900 mg – 1300 mg of lyophilized<br>fibrinogen for reconstitution.</p>
<p><span class="Bold">For Intravenous Administration<br>Only</span></p>
<p><span class="Bold">Rx only</span></p>
<p>Manufactured by:<br><span class="Bold">CSL Behring GmbH</span><br>35041 Marburg, Germany<br>US License No. 1765</p>
<p><span class="Bold">CSL Behring</span></p>
<div class="Figure"><img alt="Principal Display Panel - One Single-use Vial Carton" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=903dc8d0-39da-462c-9dac-004e0c7a26cc&amp;name=riastap-01.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>RIASTAP 		
					</strong><br><span class="contentTableReg">fibrinogen injection, powder, lyophilized, for solution</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">PLASMA DERIVATIVE</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:63833-891</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAVENOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>Fibrinogen</strong> (Fibrinogen) </td>
<td class="formItem">Fibrinogen</td>
<td class="formItem">1300 mg  in 50 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Albumin (Human)</strong></td>
<td class="formItem">700 mg  in 50 mL</td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>arginine hydrochloride</strong></td>
<td class="formItem">660 mg  in 50 mL</td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Sodium chloride</strong></td>
<td class="formItem">350 mg  in 50 mL</td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>Sodium citrate</strong></td>
<td class="formItem">100 mg  in 50 mL</td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Water</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>Sodium hydroxide</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>hydrochloric acid</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:63833-891-51</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">50 mL in 1 VIAL, SINGLE-USE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">BLA</td>
<td class="formItem">BLA125317</td>
<td class="formItem">01/16/2009</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>CSL Behring GmbH
							(326530474)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">CSL Behring GmbH</td>
<td class="formItem"></td>
<td class="formItem">326530474</td>
<td class="formItem">MANUFACTURE(63833-891)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 12/2011<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>93c22ea0-e934-4ac5-92ff-7538f503811f</div>
<div>Set id: 903dc8d0-39da-462c-9dac-004e0c7a26cc</div>
<div>Version: 6</div>
<div>Effective Time: 20111219</div>
</div>
</div> <div class="DistributorName">CSL Behring GmbH</div></p>
</body></html>
